Polyvinyl Alcohol — supply status, manufacturers & alternatives

Polyvinyl Alcohol

—

In supply · Australia

In supply · 🇦🇺 Australia · short in🇺🇸 US

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Polyvinyl Alcohol
Therapeutic category	Auto-created by FDA Drug Enforcement — Full Recall Database scraper
Controlled substance	No
Marketing-authorisation holders	RUGBY LABORATORIES, Aurolab, A-S Medication Solutions

Registrations on file	3

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Other markets

🇺🇸 US

US$0.34

Acquisition

Recalls official enforcement reports

🇺🇸

POLYVINYL ALCOHOL

BRS Analytical Services, LLC · Apr 2025

Class IIdetails ↗

🇺🇸

POLYVINYL ALCOHOL

AvKARE · Dec 2024

Class IIIdetails ↗

🇺🇸

Polyvinyl Alcohol

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · Oct 2023

Class Idetails ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders3 registrations · 3 MA holders

Product	Strength	Form	Market	MA holder	Status
Rugby Polyvinyl Alcohol 1.4% Lubricating Eye Drops	1.4g/100mL	solution	🇺🇸 US	RUGBY LABORATORIES	Active
Polyvinyl Alcohol Eye Drops 1,4 % w/v	5mg/mL	solution	🇺🇸 US	Aurolab	Active
Polyvinyl Alcohol	14mg/mL	solution	🇺🇸 US	A-S Medication Solutions	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.